[go: up one dir, main page]

GB2403222A - Tissue-specific endothelial membrane proteins - Google Patents

Tissue-specific endothelial membrane proteins Download PDF

Info

Publication number
GB2403222A
GB2403222A GB0423854A GB0423854A GB2403222A GB 2403222 A GB2403222 A GB 2403222A GB 0423854 A GB0423854 A GB 0423854A GB 0423854 A GB0423854 A GB 0423854A GB 2403222 A GB2403222 A GB 2403222A
Authority
GB
United Kingdom
Prior art keywords
tissue
specific
ligand
therapeutic moiety
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0423854A
Other versions
GB0423854D0 (en
Inventor
Paul W Roben
Anthony C Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Utah Ventures II LP
Original Assignee
Utah Ventures II LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Utah Ventures II LP filed Critical Utah Ventures II LP
Publication of GB0423854D0 publication Critical patent/GB0423854D0/en
Publication of GB2403222A publication Critical patent/GB2403222A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods and compositions for targeting of pharmaceuticals or other therapeutics to specific tissues using tissue-specific endothelial membrane proteins are provided. The compositions comprise a therapeutic complex composed of a ligand, a linker, and a therapeutic moiety, where the therapeutic moiety can enter the cell. The ligand can be an antibody or other molecule that binds to a tissue-specific protein on the endothelial membrane of a specific tissue. The ligand does not activate a receptor, but may activate endocytosis. The therapeutic moiety could be a drug, gene, antisense oligonucleotide, contrast agent, protein, toxin, or any type of molecule that acts on the specific tissue. The linker is preferably cleaved upon going to the interior of the cell. Alternatively, the linker may simply be the bond between the ligand and the therapeutic moiety. Alternatively, a lipophilic prodrug may be cleaved and may enter the cell due to its lipophilic properties.

Description

GB 2403222 A continuation (72) Inventor(s): Paul W. Roben Anthony C.
Stevens (74) Agent and/or Address for Service: Hepworth Lawrence Bryer & Bizley Merlin House, Falconry Court, Bakers Lane, EPPING, Essex, CM16 5DQ, United Kingdom
GB0423854A 2002-04-01 2003-03-31 Tissue-specific endothelial membrane proteins Withdrawn GB2403222A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945202P 2002-04-01 2002-04-01
PCT/US2003/010195 WO2003084469A2 (en) 2002-04-01 2003-03-31 Tissue-specific endothelial membrane proteins

Publications (2)

Publication Number Publication Date
GB0423854D0 GB0423854D0 (en) 2004-12-01
GB2403222A true GB2403222A (en) 2004-12-29

Family

ID=28791952

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0423854A Withdrawn GB2403222A (en) 2002-04-01 2003-03-31 Tissue-specific endothelial membrane proteins
GBGB0424024.8A Ceased GB0424024D0 (en) 2002-04-01 2004-10-29 Tissue-specific endothelial membrane proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB0424024.8A Ceased GB0424024D0 (en) 2002-04-01 2004-10-29 Tissue-specific endothelial membrane proteins

Country Status (4)

Country Link
AU (1) AU2003222185A1 (en)
CA (1) CA2481334A1 (en)
GB (2) GB2403222A (en)
WO (1) WO2003084469A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316857A1 (en) 2004-02-12 2011-05-04 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
FR2883873B1 (en) 2005-03-31 2009-07-10 Pharmamens Sarl AGE INHIBITORS
US20060239910A1 (en) 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US8153376B2 (en) 2006-09-25 2012-04-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
FI20075278A0 (en) * 2007-04-20 2007-04-20 Biotie Therapies Corp Novel completely human anti-VAP-1 monoclonal antibodies
SI2197903T1 (en) 2007-09-04 2015-02-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer 6011 Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
CA2925862A1 (en) 2013-10-01 2015-04-09 Glaxosmithkline Intellectual Property Development Limited Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
CN112535726B (en) * 2019-09-05 2023-09-12 南京安吉生物科技有限公司 Tumor marker AQUAPRIN 2 protein and application thereof
WO2024081930A1 (en) * 2022-10-14 2024-04-18 Flagship Pioneering Innovations Vii, Llc Compositions and methods for targeted delivery of therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CNS Drugs (2002); Vol 16(9), pp 579-593, Potential new methods for antiepileptic..., Fisher et al *

Also Published As

Publication number Publication date
GB0424024D0 (en) 2004-12-01
GB0423854D0 (en) 2004-12-01
CA2481334A1 (en) 2003-10-16
WO2003084469A3 (en) 2004-06-10
WO2003084469A2 (en) 2003-10-16
AU2003222185A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
WO2002100336A3 (en) Tissue-specific endothelial membrane proteins
Bargh et al. Sulfatase-cleavable linkers for antibody-drug conjugates
US6150168A (en) Nucleic acid transporter systems and methods of use
Li et al. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells
US5994109A (en) Nucleic acid transporter system and methods of use
Shin P62 and the sequestosome, a novel mechanism for protein metabolism
US10294270B2 (en) Branched linker for protein drug conjugates
AU3057297A (en) Targeted combination immunotherapy of cancer
EP1436316A4 (en) Subcellular targeting of therapeutic proteins
GB2403222A (en) Tissue-specific endothelial membrane proteins
WO2005035003A3 (en) Compositions and methods for increasing drug efficiency
FI963103A0 (en) Non-viral vector
MX2009002856A (en) Polymeric conjugates containing positively-charged moieties.
MA30474B1 (en) FORMULATIONS OF MOLECULE PEPTIDE (S) - LYOPHILIZED THERAPEUTIC ANTIBODY.
Niidome et al. Gene transfer into hepatoma cells mediated by galactose-modified α-helical peptides
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2001094547A3 (en) Molecular delivery vehicle for delivery of selected compounds to targets
WO2001085790A3 (en) Mammalian cytokine receptor subunit proteins, related reagents and methods
WO1999064576A3 (en) Human genes differentially expressed in colon cancer
WO2000005249A3 (en) Synthetic peptides and methods of use for autoimmune disease therapies
WO2001077145A3 (en) Integrin binding peptide derivatives
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
CA2285667A1 (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a
WO2002094995A3 (en) Methods and compositions using genetic package display
Tumey et al. ADME considerations for the development of biopharmaceutical conjugates using cleavable linkers

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)